ENTO price is going upThe entry should have been 10 day ago or so, but today it is breaking the highs. So I see potential going up even further. Stop loss should be in the 0.36 range. Resistance is at around $1.00
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.9954 USD
−15.79 M USD
0.00 USD
4.66 M
About Entero Therapeutics Inc.
Sector
Industry
CEO
James E. Sapirstein
Website
Headquarters
Boca Raton
Founded
2014
FIGI
BBG00DBBJ4T4
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ENTO is 0.5475 USD — it has decreased by −2.38% in the past 24 hours. Watch Entero Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Entero Therapeutics Inc. stocks are traded under the ticker ENTO.
ENTO stock has fallen by −34.20% compared to the previous week, the month change is a 13.66% rise, over the last year Entero Therapeutics Inc. has showed a −87.83% decrease.
ENTO reached its all-time high on Oct 13, 2016 with the price of 9,878,400,000.0000 USD, and its all-time low was 0.1850 USD and was reached on Aug 8, 2024. View more price dynamics on ENTO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ENTO stock is 11.20% volatile and has beta coefficient of 3.28. Track Entero Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Entero Therapeutics Inc. there?
Today Entero Therapeutics Inc. has the market capitalization of 2.71 M, it has decreased by −11.71% over the last week.
Yes, you can track Entero Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Entero Therapeutics Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ENTO net income for the last quarter is −2.58 M USD, while the quarter before that showed −8.81 M USD of net income which accounts for 70.70% change. Track more Entero Therapeutics Inc. financial stats to get the full picture.
No, ENTO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 9.00 employees. See our rating of the largest employees — is Entero Therapeutics Inc. on this list?
Like other stocks, ENTO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Entero Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Entero Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Entero Therapeutics Inc. stock shows the sell signal. See more of Entero Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.